ReviewRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2024
Respiratory syncytial virus: A new era.
Review in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Establishment and Validation of a Cell-Based Relative Potency Method for Respiratory Syncytial Virus mRNA Vaccine Drug Substance.Vaccines · 2026Article
- A guide to healthcare maintenance for the patient with inflammatory bowel disease.Annals of gastroenterology · 2026Review
- Characteristics and outcomes of hospitalized adult patients with respiratory syncytial virus infection in different age groups.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- MMP-9 regulates disulphide isomerase activity of TGM2 to enhance fusion glycoprotein-mediated syncytium formation of respiratory syncytial virus.Protein & cell · 2026Article
- Adult RSV hospitalizations in Spain: clinical characteristics and risk factors for ICU admission, prolonged stay, and mortality across six seasons (2016-2017 to 2021-2022).Frontiers in public health · 2026Article
- Observational
- In-Hospital Death and Risk Factors in Adults With Respiratory Syncytial Virus in Spain (2016-2023). A Cross-Sectional Study With Focus on Older Patients.Health science reports · 2025Article
- Respiratory syncytial virus (RSV) infections in adults: Current trends and recommendations for prevention - a global challenge from a local perspective.Human vaccines & immunotherapeutics · 2025Review
- Hospital burden of Respiratory Syncytial Virus in children in Spain (2016-2022): A retrospective study.Human vaccines & immunotherapeutics · 2025Article
- Epidemiological characteristics of pediatric respiratory pathogens and their association with climate in Wuxi, Chongqing, China.New microbes and new infections · 2025Article
- Causes and consequences of undervaccination in adults.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Review
- Guideline for the diagnosis, treatment, and prevention of respiratory syncytial virus infection in children in China.Pediatric investigation · 2025Article
- A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus.Pulmonary therapy · 2025Article
- Article
- Genetic Diversity in the Fusion Gene of Respiratory Syncytial Virus (RSV) Isolated From Iraqi Patients: A First Report.Advances in virology · 2025Article
- Article
- Article
- Clinical Features of RS Virus Infection before, during, and after COVID-19 Pandemic.Children (Basel, Switzerland) · 2024Article
- [Urolithin A alleviates respiratory syncytial virus-induced lung infection in neonatal mice by activating miR-136-mediated Sirt1 signaling].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Respiratory syncytial virus: A review of current basic and clinical knowledge.Qatar medical journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a major public health problem that has undergone significant changes in recent years. First of all, it has become easier to diagnose with highly reliable and rapidly available confirmatory tests. This has led to a better understanding of its epidemiology and RSV has gone from being a disease of the pediatric age group, severe only in infants and immunosuppressed children, to being a common disease in people of all ages, particularly important in patients of advanced age or with immunosuppressive diseases. Recent therapeutic and prophylactic advances, both with long-lasting monoclonal antibodies and vaccines, are another reason for satisfaction. For these reasons, the COVID and Emerging Pathogens Committee of the Illustrious Official College of Physicians of Madrid (ICOMEM) has considered it pertinent to review this subject in the light of new knowledge and new resources for dealing with this infection. We have formulated a series of questions that we believe will be of interest not only to members of the College but also to any non-expert in this subject, with a particular focus on the situation of RSV infection in Spain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.